Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's ...

Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...

Mosunetuzumab's subcutaneous formulation offers a 1-minute injection, improving convenience over the previous intravenous infusion for relapsed or refractory follicular lymphoma. The phase 1/2 GO29781 ...

Background: Vitamin B12 deficiency is a widespread condition, particularly among elderly individuals, patients with malabsorption syndromes, and those following plant-based diets. This systematic ...

Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...